Search Results - "Nogami, K."

Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti‐idiotype monoclonal antibodies by Nogami, K., Soeda, T., Matsumoto, T., Kawabe, Y., Kitazawa, T., Shima, M.

“…Essentials Emicizumab (Emi) affects the APTT‐based assays of factor (F)VIII activity and inhibitor titer. A mixture of two anti‐Emi monoclonal antibodies (mAb)…”
Get full text

Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti‐factor IXa/factor X bispecific antibody emicizumab by Nogami, K., Matsumoto, T., Tabuchi, Y., Soeda, T., Arai, N., Kitazawa, T., Shima, M.

“…Essentials The activated partial prothrombin time (aPTT) cannot predict the activity of emicizumab (Emi). Adjusted clot waveform analyses using a prothrombin…”
Get full text

Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI‐deficient plasma in vitro by Minami, H., Nogami, K., Yada, K., Ogiwara, K., Furukawa, S., Soeda, T., Kitazawa, T., Shima, M.

“…Summary Essentials Emicizumab mimics factor (F)VIIIa cofactor function, augments the intrinsic tenase activity. We assessed the emicizumab‐driven hemostatic…”
Get full text

Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry by Furukawa, S., Nogami, K., Ogiwara, K., Yada, K., Minami, H., Shima, M.

“…Summary Background The management of hemophilia A (HA) patients with inhibitors on bypassing therapy remains challenging. In particular, the monitoring of…”
Get full text

Clot waveform analysis using CS‐2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A by Matsumoto, T., Nogami, K., Tabuchi, Y., Yada, K., Ogiwara, K., Kurono, H., Arai, N., Shima, M.

“…Introduction A recently developed method to assess comprehensive coagulation function, clot waveform analysis (CWA), accurately detect low levels (<1 IU/dL) of…”
Get full text

Role of red blood cells in the anemia‐associated bleeding under high shear conditions by Yaoi, H., Shida, Y., Ogiwara, K., Hosokawa, K., Shima, M., Nogami, K.

“…Background Red blood cells (RBCs) contribute to hemostasis under blood‐flow, and anemia might contribute to a hemorrhagic diathesis. The majority of current…”
Get full text

Coagulation function and mechanisms in various clinical phenotypes of patients with acquired factor V inhibitors by Matsumoto, T., Nogami, K., Shima, M.

“…Summary Background The clinical phenotype of individuals with acquired factor V (A‐FV) inhibitors varies from asymptomatic (non‐B group) to life‐threatening…”
Get full text

Optimal monitoring of bypass therapy in hemophilia A patients with inhibitors by the use of clot waveform analysis by Haku, J., Nogami, K., Matsumoto, T., Ogiwara, K., Shima, M.

“…Summary Background Assays to determine the optimal hemostatic effects of bypass therapy in hemophilia A (HA) patients with inhibitors are difficult to compare…”
Get full text

Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip-based flow chamber system by Ogiwara, K., Nogami, K., Hosokawa, K., Ohnishi, T., Matsumoto, T., Shima, M.

“…Summary The diagnosis of von Willebrand disease (VWD) is difficult due to the wide spectrum of clinical phenotypes associated with this disorder. We have…”
Get full text

Assessing the clinical severity of type 1 von Willebrand disease patients with a microchip flow‐chamber system by Nogami, K., Ogiwara, K., Yada, K., Shida, Y., Takeyama, M., Yaoi, H., Minami, H., Furukawa, S., Hosokawa, K., Shima, M.

“…Essentials von Willebrand factor levels don't always reflect the severity of von Willebrand disease (VWD). Relationship between new flow system (T‐TAS®) and…”
Get full text

A new parameter in the thrombin generation assay, mean velocity to peak thrombin, reflects factor VIII activity in patients with haemophilia A by Takeyama, M., Nogami, K., Shima, M.

Get full text

The Japanese Immune Tolerance Induction (J‐ITI) study in haemophilia patients with inhibitor: Outcomes and successful predictors of ITI treatment by Nogami, K., Taki, M., Matsushita, T., Ohga, S., Oka, T., Horikoshi, Y., Amano, K., Shima, M.

“…Introduction Immune tolerance induction (ITI) was the primary therapeutic approach to eradicate inhibitors in haemophilia patients. Several large ITI…”
Get full text

Successful prophylaxis using activated prothrombin complex concentrates (aPCC) in a severe haemophilia A patient with inhibitor previously unresponsive to on‐demand daily infusions of aPCC by Furukawa, S., Nogami, K., Ogiwara, K., Yada, K., Shima, M.

Get full text

Successful perioperative haemostatic management of aortic coarctation in a 5‐week‐old infant with severe haemophilia A by Furukawa, S., Nogami, K., Yoshizawa, H., Ogiwara, K., Shima, M.

Get full text

Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti‐C2 antibody inhibiting allogeneic but not autologous factor VIII activity by Yada, K., Nogami, K., Takeyama, M., Ogiwara, K., Wakabayashi, H., Shima, M.

“…Summary Background In mild hemophilia A (MHA) patients, the risk of inhibitor development is generally low, but some factor VIII (FVIII) gene missense…”
Get full text

Activated prothrombin complex concentrate (APCC)‐mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness by Yada, K., Nogami, K., Ogiwara, K., Shima, M.

“…Summary Background and objectives Activated prothrombin complex concentrates (APCCs), utilized in bypassing therapy for hemophiliacs with inhibitor, contain…”
Get full text

Simultaneous K-edge subtraction tomography for tracing strontium using parametric X-ray radiation by Hayakawa, Y., Hayakawa, K., Kaneda, T., Nogami, K., Sakae, T., Sakai, T., Sato, I., Takahashi, Y., Tanaka, T.

“…The X-ray source based on parametric X-ray radiation (PXR) has been regularly providing a coherent X-ray beam for application studies at Nihon University…”
Get full text

The utility of VWF multimer analysis in response to the desmopressin administration for the diagnosis of severe type 1 von Willebrand disease by Takeyama, M., Nogami, K., Onaka, M., Yada, K., Shida, Y., Shima, M.

Get full text

A phase III clinical trial of a mixture agent of plasma‐derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors by Shinkoda, Y., Shirahata, A., Fukutake, K., Takamatsu, J., Shima, M., Hanabusa, H., Mugishima, H., Takedani, H., Kawasugi, K., Taki, M., Matsushita, T., Tawa, A., Nogami, K., Higasa, S., Kosaka, Y., Fujii, T., Sakai, M., Migita, M., Uchiba, M., Kawakami, K., Sameshima, K., Ohashi, Y., Saito, H.

“…Introduction MC710, a 1:10 protein weight ratio mixture of plasma‐derived activated factor VII (FVIIa) and factor X (FX), is a novel bypassing agent for…”
Get full text

Possible assessment of coagulation function and haemostasis therapy using comprehensive coagulation assays in a patient with acquired haemophilia A by Takeyama, M., Nogami, K., Matsumoto, T., Taguchi, M., Yada, K., Okahashi, N., Amano, I., Kimura, H., Shima, M.

Get full text